Cargando…

mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea

OBJECTIVES: Household contacts of confirmed cases of coronavirus disease 2019 (COVID-19) are exposed to a high risk of viral transmission, and secondary incidence is an important indicator of community transmission. This study analyzed the secondary attack rate and mRNA vaccine effectiveness against...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hanul, Park, Young Joon, Lee, Sang Eun, Lee, Min Jei, Ahn, Hyungtae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korea Disease Control and Prevention Agency 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10211438/
https://www.ncbi.nlm.nih.gov/pubmed/36617549
http://dx.doi.org/10.24171/j.phrp.2022.0243
_version_ 1785047275131633664
author Park, Hanul
Park, Young Joon
Lee, Sang Eun
Lee, Min Jei
Ahn, Hyungtae
author_facet Park, Hanul
Park, Young Joon
Lee, Sang Eun
Lee, Min Jei
Ahn, Hyungtae
author_sort Park, Hanul
collection PubMed
description OBJECTIVES: Household contacts of confirmed cases of coronavirus disease 2019 (COVID-19) are exposed to a high risk of viral transmission, and secondary incidence is an important indicator of community transmission. This study analyzed the secondary attack rate and mRNA vaccine effectiveness against transmission (VET) for index cases (patients treated at home) confirmed to be infected with the Delta and Omicron variants. METHODS: The subjects of the study were 4,450 index cases and 10,382 household contacts. Logistic regression analysis was performed to compare the secondary attack rate by vaccination status, and adjusted relative risk and 95% confidence intervals were identified. RESULTS: The secondary attack rate of the Delta variant was 27.3%, while the secondary attack rate of the Omicron variant was 29.8%. For the Delta variant, groups with less than 90 days and more than 90 days after 2 doses of mRNA vaccination both showed a VET of 37%. For the Omicron variant, a 64% VET was found among those with less than 90 days after 2 doses of mRNA vaccination. CONCLUSION: This study provides useful data on the secondary attack rate and VET of mRNA vaccines for household contacts of COVID-19 cases in South Korea.
format Online
Article
Text
id pubmed-10211438
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korea Disease Control and Prevention Agency
record_format MEDLINE/PubMed
spelling pubmed-102114382023-05-26 mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea Park, Hanul Park, Young Joon Lee, Sang Eun Lee, Min Jei Ahn, Hyungtae Osong Public Health Res Perspect Original Article OBJECTIVES: Household contacts of confirmed cases of coronavirus disease 2019 (COVID-19) are exposed to a high risk of viral transmission, and secondary incidence is an important indicator of community transmission. This study analyzed the secondary attack rate and mRNA vaccine effectiveness against transmission (VET) for index cases (patients treated at home) confirmed to be infected with the Delta and Omicron variants. METHODS: The subjects of the study were 4,450 index cases and 10,382 household contacts. Logistic regression analysis was performed to compare the secondary attack rate by vaccination status, and adjusted relative risk and 95% confidence intervals were identified. RESULTS: The secondary attack rate of the Delta variant was 27.3%, while the secondary attack rate of the Omicron variant was 29.8%. For the Delta variant, groups with less than 90 days and more than 90 days after 2 doses of mRNA vaccination both showed a VET of 37%. For the Omicron variant, a 64% VET was found among those with less than 90 days after 2 doses of mRNA vaccination. CONCLUSION: This study provides useful data on the secondary attack rate and VET of mRNA vaccines for household contacts of COVID-19 cases in South Korea. Korea Disease Control and Prevention Agency 2022-12 2022-11-28 /pmc/articles/PMC10211438/ /pubmed/36617549 http://dx.doi.org/10.24171/j.phrp.2022.0243 Text en © 2022 Korea Disease Control and Prevention Agency. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Original Article
Park, Hanul
Park, Young Joon
Lee, Sang Eun
Lee, Min Jei
Ahn, Hyungtae
mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
title mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
title_full mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
title_fullStr mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
title_full_unstemmed mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
title_short mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea
title_sort mrna vaccine effectiveness against sars-cov-2 b.1.617.2 (delta) and b.1.1.529 (omicron) variant transmission from home care cases to household contacts in south korea
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10211438/
https://www.ncbi.nlm.nih.gov/pubmed/36617549
http://dx.doi.org/10.24171/j.phrp.2022.0243
work_keys_str_mv AT parkhanul mrnavaccineeffectivenessagainstsarscov2b16172deltaandb11529omicronvarianttransmissionfromhomecarecasestohouseholdcontactsinsouthkorea
AT parkyoungjoon mrnavaccineeffectivenessagainstsarscov2b16172deltaandb11529omicronvarianttransmissionfromhomecarecasestohouseholdcontactsinsouthkorea
AT leesangeun mrnavaccineeffectivenessagainstsarscov2b16172deltaandb11529omicronvarianttransmissionfromhomecarecasestohouseholdcontactsinsouthkorea
AT leeminjei mrnavaccineeffectivenessagainstsarscov2b16172deltaandb11529omicronvarianttransmissionfromhomecarecasestohouseholdcontactsinsouthkorea
AT ahnhyungtae mrnavaccineeffectivenessagainstsarscov2b16172deltaandb11529omicronvarianttransmissionfromhomecarecasestohouseholdcontactsinsouthkorea